Early neurotrophic pharmacotherapy rescues developmental delay and Alzheimer’s-like memory deficits in the Ts65Dn mouse model of Down syndrome

@article{Kazim2017EarlyNP,
  title={Early neurotrophic pharmacotherapy rescues developmental delay and Alzheimer’s-like memory deficits in the Ts65Dn mouse model of Down syndrome},
  author={S. Kazim and J. Blanchard and R. Bianchi and K. Iqbal},
  journal={Scientific Reports},
  year={2017},
  volume={7}
}
Down syndrome (DS), caused by trisomy 21, is the most common genetic cause of intellectual disability and is associated with a greatly increased risk of early-onset Alzheimer’s disease (AD). The Ts65Dn mouse model of DS exhibits several key features of the disease including developmental delay and AD-like cognitive impairment. Accumulating evidence suggests that impairments in early brain development caused by trisomy 21 contribute significantly to memory deficits in adult life in DS. Prenatal… Expand
Prenatal to early postnatal neurotrophic treatment prevents Alzheimer-like behavior and pathology in mice
Behavioral Phenotyping for Down Syndrome in Mice
Deleterious Effects of Chronic Folate Deficiency in the Ts65Dn Mouse Model of Down Syndrome
...
1
2
...

References

SHOWING 1-10 OF 177 REFERENCES
Prenatal pharmacotherapy rescues brain development in a Down's syndrome mouse model.
Developmental abnormalities and age-related neurodegeneration in a mouse model of Down syndrome.
...
1
2
3
4
5
...